Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.
You may also be interested in...
BI/Lilly Bring Third Entrant To SGLT2 Market With Jardiance Approval
The type 2 diabetes space gets more crowded as FDA hands out another approval for an SGLT-2 inhibitor after an earlier rejection in March due to manufacturing issues.
Empagliflozin Approval May Come This Year After Boehringer Resolves GMP Problems
BI/Lilly’s SGLT-2 inhibitor is to be manufactured in a facility that was subject to a May 2013 warning letter from FDA.
Empagliflozin Approval May Come This Year After Boehringer Resolves GMP Problems
BI/Lilly’s SGLT-2 inhibitor is to be manufactured in a facility that was subject to a May 2013 warning letter from FDA.